274 related articles for article (PubMed ID: 31598469)
1. Identification of Radioactive Iodine Refractory Differentiated Thyroid Cancer.
Mu ZZ; Zhang X; Lin YS
Chonnam Med J; 2019 Sep; 55(3):127-135. PubMed ID: 31598469
[TBL] [Abstract][Full Text] [Related]
2. Radioactive iodine refractoriness in Middle Eastern differentiated thyroid cancer: clinical outcome and risk factor analysis.
Parvathareddy SK; Siraj AK; Siraj N; Ahmed SO; Al-Rasheed M; Qadri Z; Siddiqui K; Al-Sobhi SS; Al-Dayel F; Al-Kuraya KS
Front Endocrinol (Lausanne); 2024; 15():1326976. PubMed ID: 38812819
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological features of differentiated thyroid carcinoma as predictors of the effects of radioactive iodine therapy.
Liu W; Jiang B; Xue J; Liu R; Wei Y; Li P
Ann Diagn Pathol; 2024 Apr; 69():152243. PubMed ID: 38128440
[TBL] [Abstract][Full Text] [Related]
4. Characterizing Genetic Alterations Related to Radioiodine Avidity in Metastatic Thyroid Cancer.
Mu Z; Zhang X; Sun D; Sun Y; Shi C; Ju G; Kai Z; Huang L; Chen L; Liang J; Lin Y
J Clin Endocrinol Metab; 2024 Apr; 109(5):1231-1240. PubMed ID: 38060243
[TBL] [Abstract][Full Text] [Related]
5. Quantitative thyroglobulin response to radioactive iodine treatment in predicting radioactive iodine-refractory thyroid cancer with pulmonary metastasis.
Wang C; Zhang X; Li H; Li X; Lin Y
PLoS One; 2017; 12(7):e0179664. PubMed ID: 28704384
[TBL] [Abstract][Full Text] [Related]
6. Pathogenesis and signaling pathways related to iodine-refractory differentiated thyroid cancer.
Zhao S; Zhao Y; Zhao Y; Wang G
Front Endocrinol (Lausanne); 2023; 14():1320044. PubMed ID: 38313845
[TBL] [Abstract][Full Text] [Related]
7. Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine.
Jaber T; Waguespack SG; Cabanillas ME; Elbanan M; Vu T; Dadu R; Sherman SI; Amit M; Santos EB; Zafereo M; Busaidy NL
J Clin Endocrinol Metab; 2018 Oct; 103(10):3698-3705. PubMed ID: 30032208
[TBL] [Abstract][Full Text] [Related]
8. Ultrasound characteristics of cervical lesions in patients with radioiodine refractory differentiated thyroid cancer: A strobe-compliant article.
Gao L; Lin Y; Jiang Y; Li H; Gao Q; Xi X; Wang Y; Yang X; Lai X; Zhu S; Zhang X; Zhao R; Zhang B
Medicine (Baltimore); 2019 Nov; 98(45):e17876. PubMed ID: 31702656
[TBL] [Abstract][Full Text] [Related]
9. Risk stratification for radioactive iodine refractoriness using molecular alterations in distant metastatic differentiated thyroid cancer.
Mu Z; Zhang X; Liang D; Fang J; Chen G; Guo W; Sun D; Sun Y; Kai Z; Huang L; Liang J; Lin Y
Chin J Cancer Res; 2024 Feb; 36(1):25-35. PubMed ID: 38455372
[TBL] [Abstract][Full Text] [Related]
10. Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy.
Liu J; Liu Y; Lin Y; Liang J
Endocrinol Metab (Seoul); 2019 Sep; 34(3):215-225. PubMed ID: 31565873
[TBL] [Abstract][Full Text] [Related]
11. Clinical, Pathological, and Molecular Profiling of Radioactive Iodine Refractory Differentiated Thyroid Cancer.
Shobab L; Gomes-Lima C; Zeymo A; Feldman R; Jonklaas J; Wartofsky L; Burman KD
Thyroid; 2019 Sep; 29(9):1262-1268. PubMed ID: 31319763
[No Abstract] [Full Text] [Related]
12. State of the Art in the Current Management and Future Directions of Targeted Therapy for Differentiated Thyroid Cancer.
Silaghi H; Lozovanu V; Georgescu CE; Pop C; Nasui BA; Cătoi AF; Silaghi CA
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408830
[TBL] [Abstract][Full Text] [Related]
13. Radioiodine refractory differentiated thyroid cancer.
Jin Y; Van Nostrand D; Cheng L; Liu M; Chen L
Crit Rev Oncol Hematol; 2018 May; 125():111-120. PubMed ID: 29650270
[TBL] [Abstract][Full Text] [Related]
14. Radioiodine-refractory differentiated thyroid cancer: Molecular mechanisms and therapeutic strategies for radioiodine resistance.
Shen H; Zhu R; Liu Y; Hong Y; Ge J; Xuan J; Niu W; Yu X; Qin JJ; Li Q
Drug Resist Updat; 2024 Jan; 72():101013. PubMed ID: 38041877
[TBL] [Abstract][Full Text] [Related]
15. Clinical Utility of Cabozantinib in the Treatment of Locally Advanced or Metastatic Differentiated Thyroid Carcinoma: Patient Selection and Reported Outcomes.
Roof L; Geiger JL
Cancer Manag Res; 2023; 15():343-350. PubMed ID: 37070083
[TBL] [Abstract][Full Text] [Related]
16. Consensus on the management of advanced radioactive iodine-refractory differentiated thyroid cancer on behalf of the Spanish Society of Endocrinology Thyroid Cancer Working Group (GTSEEN) and Spanish Rare Cancer Working Group (GETHI).
Capdevila J; Galofré JC; Grande E; Zafón Llopis C; Ramón Y Cajal Asensio T; Navarro González E; Jiménez-Fonseca P; Santamaría Sandi J; Gómez Sáez JM; Riesco Eizaguirre G
Clin Transl Oncol; 2017 Mar; 19(3):279-287. PubMed ID: 27704399
[TBL] [Abstract][Full Text] [Related]
17. Radioactive Iodine-Refractory Differentiated Thyroid Cancer in the Elderly.
Gosain R; Alexander JS; Gill A; Perez C
Curr Oncol Rep; 2018 Sep; 20(10):82. PubMed ID: 30206719
[TBL] [Abstract][Full Text] [Related]
18. Integrin αvβ3 imaging of radioactive iodine-refractory thyroid cancer using 99mTc-3PRGD2.
Zhao D; Jin X; Li F; Liang J; Lin Y
J Nucl Med; 2012 Dec; 53(12):1872-7. PubMed ID: 23071350
[TBL] [Abstract][Full Text] [Related]
19. Theranostic Options for Radioiodine-Refractory Differentiated Thyroid Carcinoma: Recent Advances, Challenges, and Road Ahead.
Satapathy S; Bal C
Front Endocrinol (Lausanne); 2022; 13():924841. PubMed ID: 35903277
[TBL] [Abstract][Full Text] [Related]
20. Metabolomics reveals the implication of acetoacetate and ketogenic diet therapy in radioiodine-refractory differentiated thyroid carcinoma.
Wang J; Xu Q; Xuan Z; Mao Y; Tang X; Yang K; Song F; Zhu X
Oncologist; 2024 May; ():. PubMed ID: 38760956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]